Three biotechs and one regional bank priced and began trading on Wednesday. None broke issue.
Only one of the four priced below the range, compared to 85% of IPOs that began trading in October.
Advanced Accelerator Applications (AAAP)...read more
WAVE Life Sciences, a preclinical biotech developing optimized RNA therapies for rare diseases, raised $102 million by offering 6.4 million shares at $16, the midpoint of the range of $15 to $17. The company originally planned to offer 5.0 million shares....read more
Silenseed, a biotech developing RNA interference cancer drugs and delivery systems, withdrew its plans for an initial public offering on Tuesday. The company has first targeted pancreatic cancer for its combined RNA interference (RNAi) drug and delivery...read more
US IPO Weekly Recap: IPO market turns friendly as seven companies go public
As we noted in a mid-week blog post, AAAP had the best first-day pop (+53%) for an IPO in three months, and on the same...read more
Good trading if you can get it (done): Four of six IPOs price and trade up on Wednesday
Three biotechs and one regional bank priced and began trading on Wednesday. None broke issue. Only one of the four priced below the range, compared to 85% of IPOs that began trading in October. Advanced Accelerator Applications (AAAP)...read more
WAVE Life Sciences prices upsized IPO at $16 midpoint
WAVE Life Sciences, a preclinical biotech developing optimized RNA therapies for rare diseases, raised $102 million by offering 6.4 million shares at $16, the midpoint of the range of $15 to $17. The company originally planned to offer 5.0 million shares....read more
Silenced: RNA biotech Silenseed withdraws $35 million IPO
Silenseed, a biotech developing RNA interference cancer drugs and delivery systems, withdrew its plans for an initial public offering on Tuesday. The company has first targeted pancreatic cancer for its combined RNA interference (RNAi) drug and delivery...read more